Addressing Nanovaccine Strategies for Tilapia

• Published in: Vaccines
• Main Authors: Thompson, Kim D., Rodkhum, Channarong, Bunnoy, Anurak, Thangsunan, Patcharapong, Kitiyodom, Sirikorn, Sukkarun, Pimwarang, Yostawornkul, Jakarwan, Yata, Teerapong, Pirarat, Nopadon
• Format: Text
• Language: English
• Published: MDPI 2023
• Subjects: Review; Atlantic salmon
• Online Access: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10459980/; http://www.ncbi.nlm.nih.gov/pubmed/37631924; https://doi.org/10.3390/vaccines11081356

Tilapia is the world’s most extensively farmed species after carp. It is an attractive species for aquaculture as it grows quickly, reaching harvest size within six to seven months of production, and provides an important source of food and revenue for many low-income families, especially in low- to middle-income countries. The expansion of tilapia aquaculture has resulted in an intensification of farming systems, and this has been associated with increased disease outbreaks caused by various pathogens, mostly bacterial and viral agents. Vaccination is routinely used to control disease in higher-value finfish species, such as Atlantic salmon. At the same time, many tilapia farmers are often unwilling to vaccinate their fish by injection once the fish have been moved to their grow-out site. Alternative vaccination strategies are needed to help tilapia farmers accept and use vaccines. There is increasing interest in nanoparticle-based vaccines as alternative methods for delivering vaccines to fish, especially for oral and immersion administration. They can potentially improve vaccine efficacy through the controlled release of antigens, protecting antigens from premature proteolytic degradation in the gastric tract, and facilitating antigen uptake and processing by antigen-presenting cells. They can also allow targeted delivery of the vaccine at mucosal sites. This review provides a brief overview of the bacterial and viral diseases affecting tilapia aquaculture and vaccine strategies for farmed tilapia. It focuses on the use of nanovaccines to improve the acceptance and uptake of vaccines by tilapia farmers.